B-Lymphoblastic Leukemia / Lymphoma · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	aggressive
Linked regimen	`None`

ID	`IND-ETV6-CARRIER-INTENSIFIED`
Type	Indication
Status	reviewed 2026-05-20 \| pending_clinical_signoff
Diseases	`DIS-B-ALL`
Sources	`SRC-ELN-AML-2022` `SRC-ESMO-MDS-2021` `SRC-NCCN-AML-2025`

Notes

STUB — Wave P ETV6 intensified-track. §15.2 C4 ≥2-tracks invariant. Sibling — IND-ETV6-CARRIER-SURVEILLANCE (standard plan_track).

Used By

Indication

IND-ETV6-CARRIER-SURVEILLANCE - IND-ETV6-CARRIER-SURVEILLANCE

Red flag

RF-ETV6-CONFIRMED-CARRIER - Confirmed germline pathogenic / likely-pathogenic variant in ETV6 (Thrombocytopenia 5, TH...